#82 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Patients with chronic jaw and facial pain who have not found relief through standard treatments now have emerging clinical trial evidence supporting sublingual cannabis extracts as a potential therapeutic option worth discussing with their provider.
Sublingual cannabis extract administration has demonstrated meaningful reductions in myofascial pain among patients with temporomandibular disorders, a condition historically resistant to conventional pharmacological approaches. The findings add to a growing body of evidence supporting cannabinoid-based interventions for chronic orofacial pain, where inflammation and central sensitization play significant roles. Sublingual delivery offers practical advantages in this population, including rapid mucosal absorption and the ability to titrate dosing with reasonable precision.
“When a randomized trial shows significant pain reduction in one of the most undertreated and overlooked chronic pain conditions, dismissing cannabinoids as adjunct therapy becomes increasingly difficult to justify scientifically.”
This clinical trial demonstrates a meaningful therapeutic application for cannabinoid extracts in temporomandibular disorder (TMD), a condition affecting millions of patients with limited pharmacological options. The sublingual delivery method is particularly relevant clinically, as it bypasses hepatic metabolism and allows for rapid onset of action, which may explain the significant pain reduction observed in study participants. Myofascial pain represents one of the most prevalent and treatment-resistant components of TMD, making this finding noteworthy for patients who have exhausted conventional interventions. Future research should focus on identifying which cannabinoid ratios and terpene profiles optimize analgesic effects, as well as establishing optimal dosing protocols for this patient population. These results suggest that cannabis extracts warrant consideration as part of a multimodal pain management strategy for TMD-related myofascial dysfunction.
๐ฌ Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan โ
Want to discuss this topic with other patients and caregivers? Join the forum discussion โ
Have thoughts on this? Share it:
Effect of ฮ9-tetrahydrocannabinol and cannabidiol on myofascial pain modulation in patients with temporomandibular disorder: a prospective crossover study
et al. · Clinics · 2026
Open access · CC-BY